Description
Corneal thinning disorders are rare progressive disorders that can either be caused by a primary disease process (keratoconus) or may be secondary to another process; such as post laser-in-situ-keratomileusis (LASIK) induced keratectasia (KE). It has been estimated that the most common corneal thinning disorder, keratoconus (KC), affects 1 in every 2000 people globally. Corneal crosslinking using riboflavin and ultraviolet-A radiation (CXL) is an emerging technology which may be used for managing corneal thinning disorders. The purpose of this review is to determine the safety, clinical efficacy, social impact and economic value of CXL for the management of corneal thinning disorders.
Updated
July 9, 2012
Tags
Resources
Title and publication information
Type
Extent
101 pages
Frequency
Once
Publisher / Creator Information
Creator
Publisher
Health
Place of Publication
Subject Information
Topic
Resource Dates
Date Created
2012-07-09
Date Added
2017-07-07T17:06:24.579514
Date Modified
2012-07-09
Date Issued
2012-07-09
Audience information
Language
Identifiers
Usage / Licence
Usage Considerations
Health technology assessment reports were produced by partner organizations for Alberta Health and the Alberta Health Technologies Decision Process. The conclusions presented in the reports are solely those of the partner organization that produced the reports and do not represent the policies or position of the Government of Alberta, Alberta Health, or any other agency.